Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Unitorium is a brand-name generic version of the antibiotic ceftriaxone, manufactured by Uni-Tech Pharmaceutical (Pvt.) Ltd. It is a third-generation cephalosporin that exhibits broad-spectrum bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. The drug's mechanism of action involves the inhibition of bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). This binding prevents the final transpeptidation step of peptidoglycan synthesis, leading to the weakening of the cell wall and eventual osmotic lysis of the bacterium. Unitorium is primarily indicated for the treatment of serious infections, including lower respiratory tract infections, bacterial meningitis, septicemia, and urinary tract infections, and is also utilized for surgical prophylaxis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Unitorium.